HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrew W Boyd Selected Research

Ephrins

1/2024Inhibiting Eph/ephrin signaling reduces vascular leak and endothelial cell dysfunction in mice with sepsis.
1/2017Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.
2/2016EPHA4-FC TREATMENT REDUCES ISCHEMIA/REPERFUSION-INDUCED INTESTINAL INJURY BY INHIBITING VASCULAR PERMEABILITY.
1/2015EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.
12/2014Eph family co-expression patterns define unique clusters predictive of cancer phenotype.
11/2012Eph/Ephrin signaling in injury and inflammation.
3/2012Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis.
12/2011Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors.
5/2010The role of Eph receptors and ephrin ligands in colorectal cancer.
1/2010Ephrin expression and function in cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrew W Boyd Research Topics

Disease

16Neoplasms (Cancer)
01/2020 - 08/2005
9Glioblastoma (Glioblastoma Multiforme)
01/2020 - 11/2011
4Glioma (Gliomas)
12/2019 - 11/2011
4Leukemia
01/2019 - 08/2008
2Brain Neoplasms (Brain Tumor)
05/2020 - 03/2017
2Inflammation (Inflammations)
02/2016 - 11/2012
2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
03/2015 - 11/2013
2Spinal Cord Injuries (Spinal Cord Injury)
09/2012 - 01/2011
2Colorectal Neoplasms (Colorectal Cancer)
03/2012 - 05/2010
2Melanoma (Melanoma, Malignant)
08/2011 - 03/2002
1Fever (Fevers)
01/2024
1Lung Injury
01/2024
1Hepatocellular Carcinoma (Hepatoma)
01/2024
1Sepsis (Septicemia)
01/2024
1Infections
01/2024
1Hematologic Neoplasms (Hematological Malignancy)
10/2017
1Wounds and Injuries (Trauma)
01/2017
1Chronic Disease (Chronic Diseases)
01/2017
1Ischemia
02/2016
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
05/2015
1Philadelphia Chromosome
03/2015
1Tics (Tic)
03/2015
1Pathologic Processes
01/2015
1Ataxia Telangiectasia (Louis Bar Syndrome)
12/2014
1Residual Neoplasm
11/2013
1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
11/2013
1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell)
11/2013
1Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
01/2013
1Pneumonia (Pneumonitis)
11/2012
1Acute Lung Injury
11/2012
1Carcinogenesis
03/2012
1Type 2 Diabetes Mellitus (MODY)
11/2010
1Atherosclerosis
11/2010
1Neoplasm Metastasis (Metastasis)
05/2010
1Carcinoma (Carcinomatosis)
05/2010
1Confusion (Bewilderment)
04/2008
1Ovarian Neoplasms (Ovarian Cancer)
06/2006

Drug/Important Bio-Agent (IBA)

14EphrinsIBA
01/2024 - 03/2002
12Proteins (Proteins, Gene)FDA Link
01/2020 - 08/2005
8LigandsIBA
01/2024 - 06/2006
5Eph Family Receptors (Eph Receptors)IBA
01/2024 - 01/2010
4Monoclonal AntibodiesIBA
10/2017 - 02/2013
3Phosphotransferases (Kinase)IBA
01/2015 - 06/2006
2Ephrin-A1 (Ephrin A1)IBA
01/2024 - 11/2012
2Cadherins (E-Cadherin)IBA
11/2013 - 08/2011
2Messenger RNA (mRNA)IBA
11/2013 - 08/2011
2EphA4 ReceptorIBA
01/2013 - 09/2012
2EphA1 Receptor (Eph Receptor)IBA
03/2012 - 06/2006
2Tyrosine (L-Tyrosine)FDA Link
03/2012 - 06/2006
2Ephrin-A5 (AL-1)IBA
08/2005 - 03/2002
1ErythropoietinFDA Link
01/2024
1Bispecific AntibodiesIBA
05/2020
1IonophoresIBA
01/2020
1salinomycinIBA
01/2020
1Dystroglycans (Dystroglycan)IBA
12/2019
1Protein Isoforms (Isoforms)IBA
01/2019
1EphA3 ReceptorIBA
12/2018
1TriterpenesIBA
09/2017
1AntibodiesIBA
09/2017
1GlycosidesIBA
09/2017
1Immunoconjugates (Immunoconjugate)IBA
09/2017
1Immunotoxins (Immunotoxin)IBA
09/2017
1Calcitonin Receptors (Calcitonin Receptor)IBA
09/2017
1monomethyl auristatin EIBA
09/2017
1Gelonium multiflorum GEL proteinIBA
09/2017
1SO1861IBA
09/2017
1dinutuximabIBA
03/2017
1Temozolomide (Temodar)FDA LinkGeneric
03/2017
1Hormones (Hormone)IBA
03/2017
1Aromatase (CYP19)IBA
03/2017
1AndrogensIBA
03/2017
1EnzymesIBA
03/2017
1Letrozole (Femara)FDA LinkGeneric
03/2017
1Aromatase InhibitorsIBA
03/2017
1Immunoglobulin G (IgG)IBA
01/2017
1rho GTP-Binding Proteins (rho GTP-Binding Protein)IBA
02/2016
1CSL360IBA
05/2015
1Imatinib Mesylate (Gleevec)FDA Link
03/2015
1Laminin (Merosin)IBA
03/2015
1EphA2 ReceptorIBA
01/2015
1tyrosine receptor (receptor, tyrosine)IBA
01/2015
1DNA-Activated Protein KinaseIBA
12/2014
1DNA (Deoxyribonucleic Acid)IBA
12/2014
1MicroRNAs (MicroRNA)IBA
02/2014
1Mitogen-Activated Protein KinasesIBA
02/2013
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2013
1Proto-Oncogene Proteins c-etsIBA
11/2011
1Apoptosis Regulatory ProteinsIBA
11/2011
1FurinIBA
08/2011
1LipidsIBA
11/2010
1Protein Tyrosine PhosphatasesIBA
08/2008
1Indicators and Reagents (Reagents)IBA
08/2005
1SolutionsIBA
03/2002

Therapy/Procedure

11Therapeutics
01/2020 - 08/2005
2Drug Therapy (Chemotherapy)
03/2015 - 11/2011
1Ligation
01/2024
1Punctures
01/2024
1Radiotherapy
01/2020
1Immunotherapy
10/2017
1Induction Chemotherapy
03/2015